Bill Nelson actually said...

"Late last year, the AARP released a report that showed that while the Nation was in a recession... brand-name drugs were seeing some of their highest price increases in years."

"I thought in Economics 101, the free marketplace, competition, supply and demand, I thought we learned that the more that you bought in bulk, huge purchases, the more negotiating power that you had."

"for seven plans we reviewed, the average negotiated price for the cancer drug Gleevec increased by 46 percent from about $31,000 in 2006 to more than $45,000 in 2009."

"In the Senate-passed healthcare bill, the amount of the rebate for brand-name drugs is being increased for Medicaid from 15 percent to 23 percent."